C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma

Basit Öğe Kaydı
dc.contributor.authorSuner, Asli
dc.contributor.authorCarr, Brian I.
dc.contributor.authorAkkiz, Hikmet
dc.contributor.authorKarakulah, Gokhan
dc.contributor.authorUskudar, Oguz
dc.contributor.authorYalcin, Kendal
dc.contributor.authorKuran, Sedef
dc.date.accessioned2024-04-24T17:14:29Z
dc.date.available2024-04-24T17:14:29Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe hepatocellular carcinoma (HCC) tumor marker alpha-fetoprotein (AFP) is only elevated in about half of the HCC patients, limiting its usefulness in following the effects of therapy or screening. New markers are needed. It has been previously noted that the inflammation markers C-reactive protein (CRP) and platelet-lymphocyte ratio (PLR) are prognostically important and may reflect HCC aggressiveness. We therefore examined these 2 markers in a low-AFP HCC cohort and found that for HCCs > 2 cm, both markers significantly rise with an increasing maximum tumor diameter (MTD). We calculated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Youden index value for each marker, and their area-under-the-curve values for each MTD group. Patients were dichotomized into 2 groups based on the CRP and PLR from the receiver-operating characteristic curve analysis. In the logistic regression models of the 4 different MTD patient groups, CRP and PLR levels were statistically significant to estimate MTD in univariate logistic regression models of MTD groups > 2 cm. CRP and PLR were then combined, and the combination was statistically significant to estimate MTD groups of 3-, 4-, and 5-cm cutoffs. CRP and PLR thus have potential as tumor markers for low-AFP HCC patients, and possibly for screening. (C) 2018 S. Karger AG, Baselen_US
dc.description.sponsorshipNIH [CA 82723]en_US
dc.description.sponsorshipThis work was supported in part by the NIH grant CA 82723 (B.I.C).en_US
dc.identifier.doi10.1159/000492473
dc.identifier.endpage32en_US
dc.identifier.issn0030-2414
dc.identifier.issn1423-0232
dc.identifier.issue1en_US
dc.identifier.pmid30336489
dc.identifier.scopus2-s2.0-85055291651
dc.identifier.scopusqualityQ2
dc.identifier.startpage25en_US
dc.identifier.urihttps://doi.org/10.1159/000492473
dc.identifier.urihttps://hdl.handle.net/11468/17990
dc.identifier.volume96en_US
dc.identifier.wosWOS:000455066700004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectC-Reactive Proteinen_US
dc.subjectPlatelet-Lymphocyte Ratioen_US
dc.subjectNeutrophil-Lymphocyte Ratioen_US
dc.subjectHepatocellular Carcinomaen_US
dc.subjectAggressivenessen_US
dc.titleC-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinomaen_US
dc.titleC-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu